Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 301-311

  Endicott, Jean ^a   Svedsäter, Henrik ^b   Locklear, Julie C ^b  

^a NewYork Presbyterian Hospital   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Anxiety disorders; Atypical antipsychotic; Functioning; Quality of life; Randomized studies; Sleep quality

Indexed keywords

CHLORAL HYDRATE; ESCITALOPRAM; PAROXETINE; PLACEBO; QUETIAPINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ARTICLE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; FUNCTIONAL STATUS; GENERALIZED ANXIETY DISORDER; HUMAN; LIFE SATISFACTION; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PARALLEL DESIGN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PITTSBURGH SLEEP QUALITY INDEX; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE SHORT FORM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHEEHAN DISABILITY SCALE; SLEEP QUALITY; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 84930483651     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S32320     Document Type: Article

References (48)

1. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171.
2. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety. 2001;13(2): 78-88.
3. Jacobi F, Wittchen HU, Holting C, etal. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med. 2004;34(4):597-611.
4. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(5):355-364.
5. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000;15(6):319-328.
6. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry. 1993;150(4):600-607.
7. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549.
8. Ballenger JC, Davidson JRT, Lecrubier Y, etal. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 11:53-58.
9. Rogers MP, Warshaw MG, Goisman RM, etal. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders. Depress Anxiety. 1999;10(1):1-7.
10. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-First revision. World J Biol Psychiatry. 2008;9(4):248-312.
11. Pollack MH, Endicott J, Liebowitz M, etal. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008;42(12): 1042-1049.
12. Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(5):276-286.
13. Monti JM, Monti D. Sleep disturbance in generalized anxiety disorder and its treatment. Sleep Med Rev. 2000;4(3):263-276.
14. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839-1854.
15. Calabrese JR, Keck PE Jr, MacFadden W, etal. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7): 1351-1360.
16. Thase ME, MacFadden W, Weisler RH, etal. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609.
17. Katzman MA, Vermani M, Jacobs L, etal. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22(8):1480-1486.
18. Endicott J, Paulsson B, Gustafsson U, Schioler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord. 2008;111(2-3):306-319.
19. Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther. 2009;31(3):492-502.
20. Kahn RS, Schulz SC, Palazov VD, etal. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):832-842.
21. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418-428.
22. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012; 27(1):40-54.
23. Bandelow B, Chouinard G, Bobes J, etal. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305-320.
24. Magi K, Mezhebovsky I, She F, Datto C, Eriksson HA. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD). World J Biol Psychiatry. 2009;10:239.
25. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11-24.
26. Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26(8):614-628.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
28. Sheehan DV, Lecrubier Y, Sheehan KH, etal. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33.
29. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
30. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
31. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1996.
32. Wyrwich K, Harnam N, Revicki DA, Locklear JC, Svedsater H, Endicott J. Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. Int Clin Psychopharmacol. 2009;24(6):289-295.
33. Endicott J, Russell JM, Raskin J, etal. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry. 2007;68(4):518-524.
34. den Boer JA, Evans DL, Lee S, Salin-Pascual R. Unraveling the diagnostic clues of depression and GAD: the primary care challenge. Psychopharmacol Bull. 2002;36 Suppl 2:150-157.
35. Nutt D, Argyropoulos S, Hood S, Potokar J. Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol. 2006;16 Suppl 2:S109-S118.
36. Belanger L, Morin CM, Langlois F, Ladouceur R. Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptoms. J Anxiety Disord. 2004;18(4):561-571.
37. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64(10):1245-1249.
38. Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol. 1990;5(3):173-183.
39. Kennedy BL, Lin Y, Schwab JJ. Work, social, and family disabilities of subjects with anxiety and depression. South Med J. 2002;95(12): 1424-1427.
40. Pollack MH, Zaninelli R, Goddard A, etal. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350-357.
41. Rynn M, Russell J, Erickson J, etal. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008; 25(3):182-189.
42. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):19-39.
43. Weiller E, Bisserbe JC, Maier W, Lecrubier Y. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Br J Psychiatry. 1998;173 Suppl 34:18-23.
44. AstraZeneca. Seroquel XR-Summary of product characteristics for Ireland. Available from: http://www.medicines.ie/medicine/13032/SPC/Seroquel+XR+50mg%2c+150mg%2c+200mg%2c+300mg%2c+400mg+prolonged-release+tablets/. Accessed May 24, 2012.
45. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed May 24, 2012.
46. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526-539.
47. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14(6):299-313.
48. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27(10): 964-976.